CEO pay of 2008: Who makes what in Big Biotech?

Last month we brought you a list of the Top 15 Pharma CEO Paychecks. And as promised, here's a look at the five highest-paid CEOs in the biotech industry.

This year we say farewell to one of the industry's biggest stand-alone biotech companies. Genentech has been officially integrated into the Roche fold and no compensation data was available on CEO Arthur Levinson's 2008 pay. Taking Genentech and Levinson's place is Celgene's Sol Barer.

As the economic crisis continues, some biotech execs--such as Amgen's Kevin Sharer and Genzyme's Henri Treemer--saw their compensation fall from 2007 levels. But Gilead's Martin and Biogen's Mullen both enjoyed a slight pay raise in 2008. It's worth noting that all of the execs on this list make more than the CEOs of major pharma companies Bayer, AstraZeneca, Roche, Sanofi-Aventis and GlaxoSmithKline.

Since biotech companies each have their own approach to reporting CEO pay, FierceBiotech's numbers are based on total compensation reported in these companies' SEC filings. The numbers include base salary, bonus and "other" compensation in 2007. Click here to see what biotech's biggest players made last year.

- see the report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.